<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02930122</url>
  </required_header>
  <id_info>
    <org_study_id>45595</org_study_id>
    <nct_id>NCT02930122</nct_id>
  </id_info>
  <brief_title>IL-1RA Treatment in Patients With Acute ACL Tear and Painful Effusions</brief_title>
  <acronym>EASI ACL</acronym>
  <official_title>A Prospective, Single-Center, Randomized, Triple-Blinded, Placebo-Controlled Study of IL-1RA Treatment in Patients With Acute ACL Tear and Painful Effusions</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Cale Jacobs, PhD</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Kentucky</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Injury to the knee during sports participation often involves partial or full detachment of&#xD;
      the anterior cruciate ligament (abbreviated as ACL). ACL tears cause pain, swelling and&#xD;
      inflammation. While the swelling and inflammation usually goes away in time, individuals with&#xD;
      ACL injuries may experience pain and notice knee instability (knee slipping, etc.). Often&#xD;
      surgery can repair or replace the ACL within the joint, allowing individuals the ability to&#xD;
      walk or run again pain free or participate in sports. Unfortunately, osteoarthritis of the&#xD;
      knee, which also causes pain and swelling, can occur in that same knee 10-20 years later for&#xD;
      reasons which are not well understood.&#xD;
&#xD;
      In this research study, the investigator hopes to reduce the initial pre-operative pain. The&#xD;
      reduction of pain will allow for earlier movement of the knee joint and preparation for&#xD;
      surgery. The investigator is interested to see if the use of Kineret does decrease the risk&#xD;
      of developing arthritis in individuals with ACL injuries by treating them within 28 days&#xD;
      after their injury.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Kineret® was chosen because it is safe, well tolerated, and has been used to treat Rheumatoid&#xD;
      Arthritis (RA) and post-surgical persistent knee effusions as well as knee stiffness.&#xD;
      Although Kineret® is approved by the US Food and Drug Administration (FDA) for the treatment&#xD;
      of RA and Neonatal-Onset Multisystem Inflammatory Disease, it is not currently approved by&#xD;
      the FDA for use in treating ACL injury. Therefore, the use of Kineret® in this study is&#xD;
      investigational.&#xD;
&#xD;
      The research procedures will be conducted at the University of Kentucky (UK) Medical Center.&#xD;
      Participants will need to come to the UK Healthcare at Turfland located at 2195 Harrodsburg&#xD;
      Road in Lexington, KY. Participants will be asked to come to this location seven times during&#xD;
      the study. Each of those visits will take about 30 minutes. All exams and questionnaires will&#xD;
      be administered during the otherwise necessary routine visits for any participant who has&#xD;
      suffered an ACL tear. No additional visit is necessary. The total amount of time commitment&#xD;
      for participation in this study is about 6 1/2 hours, over the next 2 years.&#xD;
&#xD;
      All participants with sports related ACL injuries enrolled in this study will be seen and may&#xD;
      elect to undergo surgery, if necessary. Note: Surgery is not part of this protocol. Should&#xD;
      participants be enrolled into the study and choose not to undergo ACL reconstruction&#xD;
      (surgery), they will receive treatment according to this protocol.&#xD;
&#xD;
      Randomization: Once it has been determined that a participant qualifies for entry into the&#xD;
      study, they will be randomized, like the flipping of coin into one of two treatment groups.&#xD;
      Groups will receive knee injections with either Kineret® or a saline placebo. The saline&#xD;
      placebo will contain no active medication. Both the participant and study doctor will not&#xD;
      know what treatment group the participant is assigned to. However, in case of an emergency,&#xD;
      the investigator will be able to find out what treatment group the participant has been&#xD;
      assigned to.&#xD;
&#xD;
        -  Group 1 will receive an injection of Anakinra (Kineret®, IL-1ra; 150mg) 1-28 days after&#xD;
           ACL injury.&#xD;
&#xD;
        -  Group 2 is the placebo group. Participants enrolled into this group will receive an&#xD;
           injection of saline placebo at Visit 1.&#xD;
&#xD;
      X-rays: All participants would have undergone a routine clinical x-ray analysis at prior to&#xD;
      Visit 1.&#xD;
&#xD;
      MRI: All participants will undergo initial MRI examination to confirm ACL injury at Visit 1&#xD;
      and subsequent MRIs will be performed at Visits 5 and 6.&#xD;
&#xD;
      Participants will undergo knee aspirations. During a knee aspiration, the investigator will&#xD;
      remove fluid from the space around the knee using a needle and syringe. This is usually&#xD;
      performed under a local anesthetic to either relieve swelling or to obtain fluid for analysis&#xD;
      to diagnose a joint disorder and/or problem. Knee aspirations after ACL tear with a painful&#xD;
      effusion are a common orthopaedic practice and standard of care in at the UK Medical Center.&#xD;
      Thus they are not considered additional interventions with regard to this study unless the&#xD;
      participant has no fluid in the knee.&#xD;
&#xD;
      At Visit 1: Participants may have a large effusion that requires aspiration. This would be&#xD;
      done as part of the participants normal routine care.&#xD;
&#xD;
      At Visit 2: Should the participant elect to undergo ACL reconstruction surgery, they will&#xD;
      undergo a study required knee aspiration. This will be performed for the purpose of the&#xD;
      research.&#xD;
&#xD;
      At Visit 3: Should the participant elect to undergo ACL reconstruction surgery, and there is&#xD;
      substantial post-operative fluid in the knee, the investigator may choose to aspirate the&#xD;
      knee again. This would be done as part of the participants normal routine care.&#xD;
&#xD;
      After the aspiration procedure: Once home, it is important for the participant to keep the&#xD;
      joint aspiration site clean and dry. The aspiration site may be tender or sore for a few days&#xD;
      after the joint aspiration procedure. The investigator will instruct the participant on what&#xD;
      pain reliever they may take.&#xD;
&#xD;
      Below is breakdown of what will happen at each study visit:&#xD;
&#xD;
      Visit 1 Screening (1-28 days following injury)&#xD;
&#xD;
        -  Obtain informed consent and assent if necessary of potential subjects&#xD;
&#xD;
        -  Review medical history to determine eligibility based on inclusion/exclusion criteria.&#xD;
&#xD;
        -  MRI scheduled&#xD;
&#xD;
        -  Review medications history to determine eligibility based on inclusion/exclusion&#xD;
           criteria.&#xD;
&#xD;
        -  Perform medical examinations and collect vital signs as needed to determine eligibility&#xD;
           based on inclusion/exclusion criteria. All subjects must have a clinical exam that is&#xD;
           consistent with an ACL tear.&#xD;
&#xD;
        -  Height and weight will be recorded&#xD;
&#xD;
        -  Collection of urine and blood for laboratory testing. Women of child bearing potential&#xD;
           will be given a urine pregnancy test. Test must be negative in order to enroll into the&#xD;
           study. Parents/Legal Guardians of minor females: Your child will have a pregnancy test&#xD;
           to see if they are eligible to be in the study. The results will not be disclosed to&#xD;
           anyone other than your child, except in the case of a risk to health or welfare.&#xD;
&#xD;
        -  Subjects will have the following assessments: range of motion, knee instability&#xD;
           (Lachman's test) and standardized weight bearing x-rays. At this time the subjects will&#xD;
           also be asked to fill in a standard questionnaire covering the KOOS, IKDC, VR-12, and a&#xD;
           Likert pain scale.&#xD;
&#xD;
      Following the review of above assessment results and a review of inclusion/exclusion&#xD;
      criteria, subjects will be randomized into 1 of 2 treatment groups. Following randomization,&#xD;
      subjects will undergo a knee aspiration and will receive their first dose study medication.&#xD;
&#xD;
      Visit 2 (day of surgery or 4-6 weeks post injury)&#xD;
&#xD;
        -  Medical history&#xD;
&#xD;
        -  Medication history&#xD;
&#xD;
        -  ROM will be performed&#xD;
&#xD;
        -  Knee aspiration (in the operating room under anesthesia. This will be omitted if you do&#xD;
           not have surgery)&#xD;
&#xD;
        -  KOOS, IKDC, VR-12, and a Likert pain scale administered prior to surgery&#xD;
&#xD;
        -  Biomarkers (urine and serum) pre-operatively&#xD;
&#xD;
        -  Review AEs and SAEs&#xD;
&#xD;
      Visit 3 (4-14 days after Visit 2)&#xD;
&#xD;
        -  Knee aspiration (if clinical indicated)&#xD;
&#xD;
        -  Biomarkers (urine and serum)&#xD;
&#xD;
        -  Review for AE's and SAE's&#xD;
&#xD;
        -  ROM will be performed&#xD;
&#xD;
      Visit 4 (6 months after Visit 2)&#xD;
&#xD;
        -  Patient reported outcomes (PROs) administered&#xD;
&#xD;
        -  KOOS, IKDC, VR-12, and a Likert pain scale administered&#xD;
&#xD;
        -  ROM will be performed&#xD;
&#xD;
        -  Review of AEs and SAEs&#xD;
&#xD;
      Visit 5 (12 months after Visit 2)&#xD;
&#xD;
        -  MRI&#xD;
&#xD;
        -  Patient reported outcomes (PROs) administered&#xD;
&#xD;
        -  KOOS, IKDC, VR-12, and a Likert pain scale administered&#xD;
&#xD;
        -  Biomarkers (serum and urine only)&#xD;
&#xD;
        -  Review of AEs and SAEs&#xD;
&#xD;
        -  ROM will be performed&#xD;
&#xD;
      Visit 6 (24 months after Visit 2)&#xD;
&#xD;
        -  MRI&#xD;
&#xD;
        -  Patient reported outcomes (PROs) administered&#xD;
&#xD;
        -  KOOS, IKDC, VR-12, and a Likert pain scale administered&#xD;
&#xD;
        -  Biomarkers (urine and serum)&#xD;
&#xD;
        -  Review of AEs and SAEs&#xD;
&#xD;
        -  ROM will be performed&#xD;
&#xD;
      The blood and fluid samples collected from the participants will NOT UNDERGO GENETIC TESTING.&#xD;
      Samples will be analyzed and stored at a UK research laboratory. The will be tested for&#xD;
      special markers of cartilage breakdown and will remain property of the University of Kentucky&#xD;
      indefinitely or until they are completely used. The results from the analyzed samples are&#xD;
      important only for research For this reason, these results will not be released to either the&#xD;
      participant or their family.&#xD;
&#xD;
      Either the participant or their insurance company, Medicare or Medicaid will be responsible&#xD;
      for the costs of all care and treatment they receive during this study that they would&#xD;
      normally receive for their condition.&#xD;
&#xD;
      The University of Kentucky may not be allowed to bill an insurance company, Medicare or&#xD;
      Medicaid for the medical procedures done strictly for research. These costs include the&#xD;
      following:&#xD;
&#xD;
        -  X-ray of the knee done at Visit 1&#xD;
&#xD;
        -  Knee aspiration done at Visit 1 and Visit 3 (if necessary)&#xD;
&#xD;
      The University of Kentucky may not be allowed to bill your insurance company, Medicare or&#xD;
      Medicaid for the medical procedures done strictly for research. The following will be&#xD;
      provided at no cost to you: the injection of Kineret®, the second knee aspiration and&#xD;
      potentially the third knee aspiration, questionnaires and three MRIs.&#xD;
&#xD;
      Participants will receive $150.00 for taking part in this study. They will receive $50.00 for&#xD;
      each MRI completed. Payment will be in the form of a check which will be mailed approximately&#xD;
      four to six weeks following the study visit. If the participant is a child the compensation&#xD;
      will be mailed to the child.&#xD;
&#xD;
      Should a participant decide to withdraw from the study early they will be compensated for&#xD;
      their time and travel.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Lack of funding&#xD;
  </why_stopped>
  <start_date type="Actual">June 20, 2019</start_date>
  <completion_date type="Actual">October 16, 2020</completion_date>
  <primary_completion_date type="Actual">October 16, 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change of KOOS Symptom Score Between Groups</measure>
    <time_frame>1 year</time_frame>
    <description>KOOS symptoms scores range from 0 to 100, with higher scores indicating less severe symptoms.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in CTX-II Levels From Injury to Time of Surgery</measure>
    <time_frame>time of surgery</time_frame>
    <description>CTX-II levels measured by ELISA</description>
  </secondary_outcome>
  <other_outcome>
    <measure>MRI T1rho Changes</measure>
    <time_frame>1 year</time_frame>
    <description>MRI: T1rho values in Medial and lateral femoral condyle as wel as medial and lateral tibial plateau</description>
  </other_outcome>
  <other_outcome>
    <measure>Change in KOOS QOL Score Between Groups</measure>
    <time_frame>1 year</time_frame>
    <description>KOOS QOL</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">6</enrollment>
  <condition>Anterior Cruciate Ligament Tear</condition>
  <arm_group>
    <arm_group_label>Arm 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Intervention: anakinra (150mg) Participants will receive an intraarticular injection of anakinra (150mg) at 0-28 days post injury</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo Control</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Intervention: Saline (0.9%) Participants will receive a saline placebo injection within 28 days of injury</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>anakinra (150mg)</intervention_name>
    <description>intraarticular administration</description>
    <arm_group_label>Arm 1</arm_group_label>
    <other_name>Kineret</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Saline intraarticularly</intervention_name>
    <description>intraarticular administration</description>
    <arm_group_label>Placebo Control</arm_group_label>
    <other_name>Saline (0.9%)</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Acute ACL Tear and Painful Effusions&#xD;
&#xD;
          -  Signed and dated combined informed consent/HIPAA form and if a minor, a signed assent.&#xD;
&#xD;
          -  Willingness to comply with all study procedures and availability for the duration of&#xD;
             the study&#xD;
&#xD;
          -  For females of reproductive potential: use of highly effective contraception.&#xD;
&#xD;
          -  Currently participating in a sporting activity&#xD;
&#xD;
          -  Documentation of closed growth plates as noted on the screening x-ray&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  underlying inflammatory disease (i.e. Rheumatoid Arthritis, Psoriatic Arthritis etc)&#xD;
&#xD;
          -  have been diagnosed with hepatitis B or tuberculosis&#xD;
&#xD;
          -  currently have an infections, including infection of the skin, or have signs and&#xD;
             symptoms of an infection, including fever.&#xD;
&#xD;
          -  any abnormalities in their white blood cell counts&#xD;
&#xD;
          -  have a disease that weakens your immune system such as diabetes, cancer, HIV or AIDs&#xD;
&#xD;
          -  other major medical condition requiring treatment with immunosuppressant or modulating&#xD;
             drugs.&#xD;
&#xD;
          -  A history of chronic use of non-steroidal anti-inflammatory drugs&#xD;
&#xD;
          -  Currently taking immunosuppressant medication, including oral and parenteral&#xD;
             corticosteroids (topical and stable dose inhaled corticosteriods are acceptable)&#xD;
&#xD;
          -  Females who are pregnant or breastfeeding&#xD;
&#xD;
          -  Received a &quot;live&quot; vaccine (smallpox, MMR (measles, mumps and rubella), flu, polio,&#xD;
             typhoid, chicken pox, yellow fever, herpes zoster) 4 weeks prior to screening.&#xD;
&#xD;
          -  A history of bleeding disorders or are taking any blood thinning medications, aspirin&#xD;
             or other medications affecting blood clotting.&#xD;
&#xD;
          -  Previous exposure or allergic reaction to anakinra&#xD;
&#xD;
          -  Allergy to latex or tape&#xD;
&#xD;
          -  Allergy to Kineret or have had a reaction to any local or general anesthesia&#xD;
&#xD;
          -  prior knee surgery (contralateral)&#xD;
&#xD;
          -  have received any investigational drug with 4 weeks of study Visit 1&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>14 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Austin Stone, MD</last_name>
    <role>Study Chair</role>
    <affiliation>University of Kentucky</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>UK Healthcare at Turfland</name>
      <address>
        <city>Lexington</city>
        <state>Kentucky</state>
        <zip>40504</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>October 7, 2016</study_first_submitted>
  <study_first_submitted_qc>October 7, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 12, 2016</study_first_posted>
  <results_first_submitted>October 4, 2021</results_first_submitted>
  <results_first_submitted_qc>October 4, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">October 27, 2021</results_first_posted>
  <last_update_submitted>October 4, 2021</last_update_submitted>
  <last_update_submitted_qc>October 4, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 27, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>University of Kentucky</investigator_affiliation>
    <investigator_full_name>Cale Jacobs, PhD</investigator_full_name>
    <investigator_title>Assistant Professor Research</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anterior Cruciate Ligament Injuries</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Interleukin 1 Receptor Antagonist Protein</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>March 3, 2020</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/22/NCT02930122/Prot_SAP_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Informed Consent Form</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>Yes</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>March 24, 2020</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/22/NCT02930122/ICF_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>An insufficient number of participants were consented to generate meaningful data for this study.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Arm 1</title>
          <description>Intervention: anakinra (150mg) Participants will receive an intraarticular injection of anakinra (150mg) at 0-28 days post injury&#xD;
anakinra (150mg): intraarticular administration</description>
        </group>
        <group group_id="P2">
          <title>Placebo Control</title>
          <description>Intervention: Saline (0.9%) Participants will receive a saline placebo injection within 28 days of injury&#xD;
Saline intraarticularly: intraarticular administration</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>An insufficient number of participants were consented to generate meaningful data for this study.</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>6 participants had been enrolled at the time the study was closed (3 participants in each group)</population>
      <group_list>
        <group group_id="B1">
          <title>Arm 1</title>
          <description>Intervention: anakinra (150mg) Participants will receive an intraarticular injection of anakinra (150mg) at 0-28 days post injury&#xD;
anakinra (150mg): intraarticular administration</description>
        </group>
        <group group_id="B2">
          <title>Placebo Control</title>
          <description>Intervention: Saline (0.9%) Participants will receive a saline placebo injection within 28 days of injury&#xD;
Saline intraarticularly: intraarticular administration</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="3"/>
            <count group_id="B2" value="3"/>
            <count group_id="B3" value="6"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="16" lower_limit="16" upper_limit="17"/>
                    <measurement group_id="B2" value="18" lower_limit="14" upper_limit="21"/>
                    <measurement group_id="B3" value="17" lower_limit="14" upper_limit="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="5"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>KOOS Symptom Score</title>
          <units>units on a scale</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="14" lower_limit="10" upper_limit="16"/>
                    <measurement group_id="B2" value="15" lower_limit="11" upper_limit="15"/>
                    <measurement group_id="B3" value="14.5" lower_limit="10" upper_limit="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change of KOOS Symptom Score Between Groups</title>
        <description>KOOS symptoms scores range from 0 to 100, with higher scores indicating less severe symptoms.</description>
        <time_frame>1 year</time_frame>
        <population>An insufficient number of participants were consented to generate meaningful data for this study.</population>
        <group_list>
          <group group_id="O1">
            <title>Arm 1</title>
            <description>Intervention: anakinra (150mg) Participants will receive an intraarticular injection of anakinra (150mg) at 0-28 days post injury&#xD;
anakinra (150mg): intraarticular administration</description>
          </group>
          <group group_id="O2">
            <title>Placebo Control</title>
            <description>Intervention: Saline (0.9%) Participants will receive a saline placebo injection within 28 days of injury&#xD;
Saline intraarticularly: intraarticular administration</description>
          </group>
        </group_list>
        <measure>
          <title>Change of KOOS Symptom Score Between Groups</title>
          <description>KOOS symptoms scores range from 0 to 100, with higher scores indicating less severe symptoms.</description>
          <population>An insufficient number of participants were consented to generate meaningful data for this study.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in CTX-II Levels From Injury to Time of Surgery</title>
        <description>CTX-II levels measured by ELISA</description>
        <time_frame>time of surgery</time_frame>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>MRI T1rho Changes</title>
        <description>MRI: T1rho values in Medial and lateral femoral condyle as wel as medial and lateral tibial plateau</description>
        <time_frame>1 year</time_frame>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Change in KOOS QOL Score Between Groups</title>
        <description>KOOS QOL</description>
        <time_frame>1 year</time_frame>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>1 year</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Arm 1</title>
          <description>Intervention: anakinra (150mg) Participants will receive an intraarticular injection of anakinra (150mg) at 0-28 days post injury&#xD;
anakinra (150mg): intraarticular administration</description>
        </group>
        <group group_id="E2">
          <title>Placebo Control</title>
          <description>Intervention: Saline (0.9%) Participants will receive a saline placebo injection within 28 days of injury&#xD;
Saline intraarticularly: intraarticular administration</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Cale Jacobs</name_or_title>
      <organization>University of Kentucky</organization>
      <phone>859-218-3065</phone>
      <email>cale.jacobs@uky.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

